Abivax S.A.
ABVX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001956827
No open-market purchases or sales by Abivax S.A. insiders were filed in the last 90 days; 303 institutions reported holding it in 13F filings for Q2 2026, worth $7.20B in total; Maverick Capital is the only superinvestor holding it.
Other share classesAAVXF
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +52 vs. previous quarter
- 303
- 13F valueReported value at the end of Q2 2026
- $7.20B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding ABVX, Q2 2026
1 superinvestor reports holding Abivax S.A. on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
Open-market purchases and sales by Abivax S.A. insiders from Form 4, newest first.
No open-market purchases or sales by Abivax S.A. insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Abivax S.A. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 6,007,834 | $800.6M | 19.24% | −473,251−7.3% | Reduced |
| Helikon Investments Ltd | 2,787,131 | $371.4M | 11.10% | +1,773,807+175.0% | Added |
| Darwin Global Management, Ltd. | 3,621,583 | $348.2M | 9.26% | +152,926+4.4% | Added |
| Vestal Point Capital, LP | 2,349,443 | $313.1M | 7.32% | +849,443+56.6% | Added |
| Jupiter Topco LLC | 1,913,933 | $255.1M | 0.10% | +1,913,933 | New |
| UBS Group AG | 1,844,918 | $245.9M | 0.04% | −2,702,488−59.4% | Reduced |
| ADAR1 Capital Management, LLC | 1,804,703 | $240.5M | 11.30% | +410,684+29.5% | Added |
| Caligan Partners LP | 1,557,924 | $207.6M | 10.02% | +96,000+6.6% | Added |
| Citadel Advisors LLC | 1,438,352 | $191.7M | 0.11% | +894,014+164.2% | Added |
| Morgan Stanley | 1,432,185 | $190.9M | 0.01% | −272,773−16.0% | Reduced |